[go: up one dir, main page]

AP2006003619A0 - Novel quinoline derivatives - Google Patents

Novel quinoline derivatives

Info

Publication number
AP2006003619A0
AP2006003619A0 AP2006003619A AP2006003619A AP2006003619A0 AP 2006003619 A0 AP2006003619 A0 AP 2006003619A0 AP 2006003619 A AP2006003619 A AP 2006003619A AP 2006003619 A AP2006003619 A AP 2006003619A AP 2006003619 A0 AP2006003619 A0 AP 2006003619A0
Authority
AP
ARIPO
Prior art keywords
quinoline derivatives
novel quinoline
novel
derivatives
quinoline
Prior art date
Application number
AP2006003619A
Other languages
English (en)
Inventor
Yufeng Hong
Robert Steven Kania
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2006003619(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003619A0 publication Critical patent/AP2006003619A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003619A 2003-12-23 2004-12-13 Novel quinoline derivatives AP2006003619A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53272503P 2003-12-23 2003-12-23
PCT/IB2004/004151 WO2005063739A1 (en) 2003-12-23 2004-12-13 Novel quinoline derivatives

Publications (1)

Publication Number Publication Date
AP2006003619A0 true AP2006003619A0 (en) 2006-06-30

Family

ID=34738830

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003619A AP2006003619A0 (en) 2003-12-23 2004-12-13 Novel quinoline derivatives

Country Status (33)

Country Link
US (2) US7381824B2 (xx)
EP (1) EP1699780A1 (xx)
JP (1) JP4503022B2 (xx)
KR (1) KR100807920B1 (xx)
CN (1) CN1890234A (xx)
AP (1) AP2006003619A0 (xx)
AR (1) AR048292A1 (xx)
AU (1) AU2004309166B2 (xx)
BR (1) BRPI0418102A (xx)
CA (1) CA2551508C (xx)
CR (1) CR8482A (xx)
EA (1) EA009994B1 (xx)
EC (1) ECSP066671A (xx)
GE (1) GEP20084572B (xx)
GT (1) GT200400274A (xx)
HN (1) HN2004000544A (xx)
IL (1) IL175947A (xx)
IS (1) IS8439A (xx)
MA (1) MA28396B1 (xx)
MX (1) MXPA06007242A (xx)
MY (1) MY139446A (xx)
NL (1) NL1027847C2 (xx)
NO (1) NO20063382L (xx)
NZ (1) NZ547009A (xx)
OA (1) OA13349A (xx)
PE (1) PE20050757A1 (xx)
SG (1) SG141459A1 (xx)
TN (1) TNSN06200A1 (xx)
TW (1) TWI331148B (xx)
UA (1) UA82577C2 (xx)
UY (1) UY28692A1 (xx)
WO (1) WO2005063739A1 (xx)
ZA (1) ZA200603657B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG141459A1 (en) * 2003-12-23 2008-04-28 Pfizer Novel quinoline derivatives
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
MX2008001838A (es) * 2005-08-08 2008-04-09 Pfizer Sales y polimorfos de un inhibidor de vegf-r.
WO2007066181A2 (en) * 2005-12-05 2007-06-14 Pfizer Products Inc. Methods of preparing a vegf-r inhibitor
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
PL2154967T3 (pl) 2007-04-16 2014-08-29 Hutchison Medipharma Entpr Ltd Pochodne pirymidyny
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2680844B1 (en) 2011-03-04 2016-10-19 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
FR2973703A1 (fr) * 2011-04-08 2012-10-12 Univ Provence Aix Marseille 1 Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9650364B2 (en) 2013-02-21 2017-05-16 GlaxoSmithKline Intellectual Property Development Limted Quinazolines as kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN103524409B (zh) * 2013-09-26 2015-09-02 上海仁力医药科技有限公司 喹啉类化合物及其制备方法与应用
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
US10654808B2 (en) 2015-04-07 2020-05-19 Guangdong Raynovent Biotech Co., Ltd. Tyrosine kinase inhibitor and pharmaceutical composition comprising same
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2018059534A1 (zh) * 2016-09-30 2018-04-05 广东众生药业股份有限公司 酪氨酸激酶抑制剂的晶型、盐型以及制备方法
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
FR3080620B1 (fr) 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
AU2020271855B2 (en) * 2019-04-12 2025-11-27 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
WO2023138674A1 (zh) * 2022-01-21 2023-07-27 默达药物（香港）有限公司 N-羟基喹啉甲酰胺化合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (xx) 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
JPS62168137A (ja) 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH06504294A (ja) 1991-08-02 1994-05-19 ファイザー・インコーポレーテッド 免疫刺激剤としてのキノリン誘導体
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU686843B2 (en) 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (xx) 1994-11-12 1997-12-01 Zeneca Ltd
ES2161290T3 (es) 1995-03-30 2001-12-01 Pfizer Derivados de quinazolina.
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
ATE308527T1 (de) 1996-06-24 2005-11-15 Pfizer Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
BR9709974A (pt) 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0946554A1 (en) 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
SK286779B6 (sk) 1997-02-19 2009-05-07 Berlex Laboratories, Inc. N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
JP2001525816A (ja) 1997-05-12 2001-12-11 ザ ケネディー インスティチュート オブ リューマトロジー 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
WO1999061422A1 (en) 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
HUP0103520A3 (en) * 1998-09-29 2003-01-28 Wyeth Holdings Corp Madison Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
WO2000038786A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
HU230789B1 (en) 1999-01-22 2018-05-02 Kyowa Hakko Kirin Co Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
DK1154774T3 (da) 1999-02-10 2005-09-26 Astrazeneca Ab Quinazolinderivater som angiogenesisinhibitorer
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
DE60018216T2 (de) 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
WO2001070268A1 (en) 2000-03-22 2001-09-27 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
KR20020087453A (ko) 2000-03-31 2002-11-22 임클론 시스템즈 인코포레이티드 혈관 내피 성장 인자 수용체 길항제를 사용한, 포유동물의비충실성 종양의 치료 방법
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2407858C (en) 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US7371765B2 (en) * 2000-08-09 2008-05-13 Astrazeneca Ab Quinoline derivatives having VEGF inhibiting activity
KR100389127B1 (ko) 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
WO2002030453A1 (en) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
US20040034026A1 (en) 2000-11-22 2004-02-19 Wood Jeannette M Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2002064170A1 (en) 2001-02-09 2002-08-22 Children's Medical Center Corporation A method for treating cancer and increasing hematocrit levels
JP2005515967A (ja) 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
JP4383870B2 (ja) 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
MXPA04003878A (es) 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
AU2003206068A1 (en) * 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
CA2488739A1 (en) 2002-08-30 2004-03-11 Eisai Co., Ltd. Nitrogen-containing aromatic derivatives
SG141459A1 (en) * 2003-12-23 2008-04-28 Pfizer Novel quinoline derivatives

Also Published As

Publication number Publication date
AU2004309166A1 (en) 2005-07-14
UA82577C2 (xx) 2008-04-25
NL1027847A1 (nl) 2005-06-27
MY139446A (en) 2009-10-30
NZ547009A (en) 2009-09-25
IS8439A (is) 2006-05-04
CA2551508C (en) 2011-08-09
MA28396B1 (fr) 2007-01-02
CA2551508A1 (en) 2005-07-14
US7923457B2 (en) 2011-04-12
TW200526218A (en) 2005-08-16
CN1890234A (zh) 2007-01-03
EP1699780A1 (en) 2006-09-13
KR100807920B1 (ko) 2008-02-27
KR20060101548A (ko) 2006-09-25
EA200600892A1 (ru) 2006-12-29
IL175947A (en) 2012-08-30
MXPA06007242A (es) 2006-08-18
US20090069316A1 (en) 2009-03-12
OA13349A (en) 2007-04-13
WO2005063739A1 (en) 2005-07-14
IL175947A0 (en) 2006-10-05
US7381824B2 (en) 2008-06-03
JP2007516273A (ja) 2007-06-21
ZA200603657B (en) 2007-08-29
AR048292A1 (es) 2006-04-19
GT200400274A (es) 2005-09-20
PE20050757A1 (es) 2005-10-31
BRPI0418102A (pt) 2007-04-27
NO20063382L (no) 2006-09-20
JP4503022B2 (ja) 2010-07-14
TNSN06200A1 (fr) 2007-11-15
NL1027847C2 (nl) 2006-04-19
TWI331148B (en) 2010-10-01
UY28692A1 (es) 2005-07-29
SG141459A1 (en) 2008-04-28
GEP20084572B (en) 2008-12-25
AU2004309166B2 (en) 2008-02-21
EA009994B1 (ru) 2008-06-30
US20050137395A1 (en) 2005-06-23
CR8482A (es) 2007-12-17
ECSP066671A (es) 2006-10-25
HN2004000544A (es) 2010-06-09

Similar Documents

Publication Publication Date Title
IL175947A0 (en) Novel quinoline derivatives
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
IL164324A0 (en) Quinolinone derivatives
PL378559A1 (pl) Pochodne piperydynobenzenosulfonoamidu
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
HUS1400037I1 (hu) Új 2-piridiletilbenzamid származékok
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
ZA200500294B (en) Novel 2-pyridylethylbenzamide derivative
IL176562A0 (en) Amidopyrazole derivative
PL376997A1 (pl) Pochodne tetrahydrochinoliny
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL377318A1 (pl) Pochodne tetrahydrochinoliny
EP1694330A4 (en) DERIVATIVES OF VINORELBINE
GB0104422D0 (en) Quinoline derivative
SI1706373T1 (sl) Amidoacetonitrilni derivati
EG24415A (en) Quinoline derivatives
AU2003274551A1 (en) Quinoline derivatives
GB0611515D0 (en) Novel oxy-nitriles
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
AU2003280821A8 (en) Beauveriolide derivative
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives